Lilly Shares Drop After Roche Announces Result Of Obesity Drug
Shares of Eli Lilly and Co. took a two-day slide after competitor Roche announced positive results in an early-stage study on its obesity drug.
Read MoreShares of Eli Lilly and Co. took a two-day slide after competitor Roche announced positive results in an early-stage study on its obesity drug.
Read MoreThe U.S. Food and Drug Administration approved Eli Lilly and Company’s Zepbound injection, the first and only obesity treatment of its kind that activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors.
Read More